Periampullary Cancer ESPAC-3(v2) trial: a Randomised Controlled Phase III Trial of Adjuvant Chemotherapy Versus Observation in Patients With Periampullary Adenocarcinomas of the Head of the Pancreas

被引：0
|
作者：
Neoptolemos, J. [1 ]
Moore, M.
Cox, T. [1 ]
Valle, J. [2 ]
Palmer, D. [1 ]
Mcdonald, A. [3 ]
Carter, R. [4 ]
Tebbutt, N. [5 ]
Dervenis, C. [6 ]
Smith, D. [1 ]
Glimelius, B. [7 ]
Coxon, F. [8 ]
Lacaine, F. [9 ]
Middleton, M. [10 ]
Ghaneh, P. [1 ]
Bassi, C. [11 ]
Halloran, C. [1 ]
Olah, A. [12 ]
Rawcliffe, C. [1 ]
Buechler, M. [13 ]
机构：
[1] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[2] Christie, Manchester, Lancs, England
[3] Univ Birmingham, Birmingham B15 2TT, W Midlands, England
[4] Glasgow Royal Infirm, Glasgow, Lanark, Scotland
[5] Austin Hosp, Heidelberg, Vic 3084, Australia
[6] Aiga Olga, Athens, Greece
[7] Univ Uppsala Hosp, Uppsala, Sweden
[8] No Canc Ctr, Newcastle Upon Tyne, Tyne & Wear, England
[9] Hosp Tenon, Paris, France
[10] John Radcliffe Hosp, Oxford OX3 9DU, England
[11] Univ Verona, I-37100 Verona, Italy
[12] Petz Aladar Hosp, Gyor, Hungary
[13] Univ Heidelberg, D-6900 Heidelberg, Germany
来源：
PANCREAS | 2011年 / 40卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1343 / 1343
页数：1
相关论文
共 50 条
  • [41] Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
    Fujitani, Kazumasa
    Yang, Han-Kwang
    Mizusawa, Junki
    Kim, Young-Woo
    Terashima, Masanori
    Han, Sang-Uk
    Iwasaki, Yoshiaki
    Hyung, Woo Jin
    Takagane, Akinori
    Park, Do Joong
    Yoshikawa, Takaki
    Hahn, Seokyung
    Nakamura, Kenichi
    Park, Cho Hyun
    Kurokawa, Yukinori
    Bang, Yung-Jue
    Park, Byung Joo
    Sasako, Mitsuru
    Tsujinaka, Toshimasa
    LANCET ONCOLOGY, 2016, 17 (03): : 309 - 318
  • [42] Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Mizusawa, Junki
    Kinugasa, Yusuke
    Kanemitsu, Yukihide
    Ohue, Masayuki
    Fujii, Shoichi
    Takiguchi, Nobuhiro
    Yatsuoka, Toshimasa
    Takii, Yasumasa
    Ojima, Hitoshi
    Masuko, Hiroyuki
    Kubo, Yoshiro
    Mishima, Hideyuki
    Yamaguchi, Takashi
    Bando, Hiroyuki
    Sato, Toshihiko
    Kato, Takeshi
    Nakamura, Kenichi
    Fukuda, Haruhiko
    Moriya, Yoshihiro
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (01): : 47 - 56
  • [43] Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
    Goss, Paul E.
    Smith, Ian E.
    O'Shaughnessy, Joyce
    Ejlertsen, Bent
    Kaufmann, Manfred
    Boyle, Frances
    Buzdar, Aman U.
    Fumoleau, Pierre
    Gradishar, William
    Martin, Miguel
    Moy, Beverly
    Piccart-Gebhart, Martine
    Pritchard, Kathleen I.
    Lindquist, Deborah
    Chavarri-Guerra, Yanin
    Aktan, Gursel
    Rappold, Erica
    Williams, Lisa S.
    Finkelstein, Dianne M.
    LANCET ONCOLOGY, 2013, 14 (01): : 88 - 96
  • [44] Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
    Nutting, Christopher M.
    Morden, James P.
    Harrington, Kevin J.
    Urbano, Teresa Guerrero
    Bhide, Shreerang A.
    Clark, Catharine
    Miles, Elizabeth A.
    Miah, Aisha B.
    Newbold, Kate
    Tanay, MaryAnne
    Adab, Fawzi
    Jefferies, Sarah J.
    Scrase, Christopher
    Yap, Beng K.
    A'Hern, Roger P.
    Sydenham, Mark A.
    Emson, Marie
    Hall, Emma
    LANCET ONCOLOGY, 2011, 12 (02): : 127 - 136
  • [45] Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
    Albain, Kathy S.
    Barlow, William E.
    Ravdin, Peter M.
    Farrar, William B.
    Burton, Gary V.
    Ketchel, Steven J.
    Cobau, Charles D.
    Levine, Ellis G.
    Ingle, James N.
    Pritchard, Kathleen I.
    Lichter, Allen S.
    Schneider, Daniel J.
    Abeloff, Martin D.
    Henderson, I. Craig
    Muss, Hyman B.
    Green, Stephanie J.
    Lew, Danika
    Livingston, Robert B.
    Martino, Silvana
    Osborne, C. Kent
    LANCET, 2009, 374 (9707): : 2055 - 2063
  • [46] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Santinami, Mario
    Testori, Alessandro
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Hauschild, Axel
    Musat, Elena
    Spatz, Alain
    Keilholz, Ulrich
    LANCET, 2008, 372 (9633): : 117 - 126
  • [47] Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Eggermont, AMM
    Suciu, S
    MacKie, R
    Ruka, W
    Testori, A
    Kruit, W
    Punt, CJA
    Delauney, M
    Sales, F
    Groenewegen, G
    Ruiter, DJ
    Jagiello, I
    Stoitchkov, K
    Keilholz, U
    Lienard, D
    LANCET, 2005, 366 (9492): : 1189 - 1196
  • [48] 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
    Pivot, Xavier
    Romieu, Gilles
    Debled, Marc
    Pierga, Jean-Yves
    Kerbrat, Pierre
    Bachelot, Thomas
    Lortholary, Alain
    Espie, Marc
    Fumoleau, Pierre
    Serin, Daniel
    Jacquin, Jean-Philippe
    Jouannaud, Christelle
    Rios, Maria
    Abadie-Lacourtoisie, Sophie
    Tubiana-Mathieu, Nicole
    Cany, Laurent
    Catala, Stephanie
    Khayat, David
    Pauporte, Iris
    Kramar, Andrew
    LANCET ONCOLOGY, 2013, 14 (08): : 741 - 748
  • [49] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
    Gianni, Luca
    Eiermann, Wolfgang
    Semiglazov, Vladimir
    Manikhas, Alexey
    Lluch, Ana
    Tjulandin, Sergey
    Zambetti, Milvia
    Vazquez, Federico
    Byakhow, Mikhail
    Lichinitser, Mikhail
    Angel Climent, Miguel
    Ciruelos, Eva
    Ojeda, Belen
    Mansutti, Mauro
    Bozhok, Alla
    Baronio, Roberta
    Feyereislova, Andrea
    Barton, Claire
    Valagussa, Pinuccia
    Baselga, Jose
    LANCET, 2010, 375 (9712): : 377 - 384
  • [50] Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study)
    Uesaka, Katsuhiko
    Fukutomi, Akira
    Boku, Narikazu
    Kanemoto, Hideyuki
    Konishi, Masaru
    Matsumoto, Ippei
    Kaneoka, Yuji
    Shimizu, Yasuhiro
    Nakamori, Shoji
    Sakamoto, Hirohiko
    Morinaga, Soichiro
    Kainuma, Osamu
    Imai, Koji
    Sata, Naohiro
    Hishinuma, Shoichi
    Nakamura, Takayuki
    Kanai, Michio
    Hirano, Satoshi
    Yoshikawa, Yukinobu
    Ohashi, Yasuo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345